NLM Gateway
A service of the U.S. National Institutes of Health
Your Entrance to
Resources from the
National Library of Medicine
    Home      Term Finder      Limits/Settings      Search Details      History      My Locker        About      Help      FAQ    
Skip Navigation Side Barintended for web crawlers only
 

Fansidar for prophylaxis of pneumocystis carinii pneumonia and toxoplasmic encephalitis in AIDS patients with poor compliance.

Casado JL, Antela A, Perez-Elias MJ, Frutos B, Moreno A, Redondo E, Martin-Davila P, Guerrero A; International Conference on AIDS.

Int Conf AIDS. 1996 Jul 7-12; 11: 316 (abstract no. Tu.B.2297).

Hospital Ramon y Cajal, Madrid, Spain. Fax: 341-3368672.

Objective: To determine the safety and efficacy of fansidar as prophylaxis against P.carinii pneumonia (PCP) and toxoplasmic encephalitis (TE) in an AIDS population with poor compliance to other prophylactic regimens. Methods: A review of medical records of 70 patients receiving fansidar (one tablet weekly) since 1987 as primary or secondary prophilaxis against PCP. Results: Fansidar was administered for 904 patient-months (mean 13 months). Suspected or confirmed non-compliance with trimethoprim-sulfamethoxazole (TMP-SMX) and aerosolized pentamidine (PA) was the main reason for fansidar use in 54.2% of patients. In the remaining 45.7% there were non-serious previous reactions with TMP-SMX. Twenty patients (28.6%) received fansidar as secondary prophylaxis. Compliance with fansidar was considered adequate in 91.4% of the cases. Mean CD4 cell count was of 90 cell/microliters (1-212). For patients receiving primary prophylaxis, none developed PCP. Of those receiving secondary prophylaxis, seven out of 20 (35%) developed PCP, two of them associated with poor compliance, in a mean time of 8 months. Probability of remaining free of PCP was 75% at 24 months. Twenty-four patients were seropositive for Toxoplasma gondii and two of them (8.3%) developed TE on fansidar prophylaxis. Drug discontinuation due to toxicity was observed in 18 patients (27.3%); however serious adverse events (anaphylaxis or Stevens-Johnson syndrome) ocurred only in 3 patients (4.2%). No patient death was attributed to fansidar prophylaxis. Conclusions: Fansidar weekly appears to be effective as prophylaxis for PCP and TE in AIDS patients with poor compliance to TMP-SMX or PA.

Publication Types:
  • Meeting Abstracts
Keywords:
  • Acquired Immunodeficiency Syndrome
  • Animals
  • Antiretroviral Therapy, Highly Active
  • Drug Combinations
  • Encephalitis
  • Humans
  • Pentamidine
  • Pneumonia, Pneumocystis
  • Pyrimethamine
  • Sulfadoxine
  • Toxoplasma
  • Trimethoprim-Sulfamethoxazole Combination
  • drug therapy
  • prevention & control
  • sulfadoxine-pyrimethamine
  • therapy
Other ID:
  • 96922499
UI: 102218398

From Meeting Abstracts




Contact Us
U.S. National Library of Medicine |  National Institutes of Health |  Health & Human Services
Privacy |  Copyright |  Accessibility |  Freedom of Information Act |  USA.gov